Global Cancer Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product;

Next-Generation Sequencing , Microarrays, In Situ Hybridization, Polymerase Chain Reaction (PCR), Flow Cytometry, Immunohistochemistry , Magnetic Resonance Imaging (MRI), Computed Tomography (CT) , Positron Emission Tomography (PET) , Ultrasound, Biopsy , Mammography, and Others.

By Coverage;

Public Insurance and Private Insurance.

By Test Type;

Biopsy - [Fine-Needle Aspiration, Core Biopsy, Surgical Biopsy, Skin Biopsy /Punch Biopsy, and Others], and Others.

By Application;

Colorectal Cancer, Breast Cancer , Lung Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn156784758 Published Date: April, 2025 Updated Date: May, 2025

Cancer Diagnostics Market Overview

Cancer Diagnostics Market (USD Million)

In the year 2024, the Cancer Diagnostics Market was valued at USD 148,570.42 million. The size of this market is expected to increase to USD 250,038.44 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.7%.


Global Cancer Diagnostics Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 7.7 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.7 %
Market Size (2024)USD 148,570.42 Million
Market Size (2031)USD 250,038.44 Million
Market ConcentrationMedium
Report Pages353
148,570.42
2024
250,038.44
2031

Major Players

  • Abbott
  • Qiagen
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc
  • GE Healthcare
  • Hologic Inc
  • Illumina Inc
  • Philips Healthcare

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Cancer Diagnostics Market

Fragmented - Highly competitive market without dominant players


The Cancer Diagnostics Market has experienced a notable surge in demand due to increasing awareness about the importance of early detection. Enhanced screening techniques and public initiatives have contributed to a rise in diagnostic procedures by over 35%. Innovations in biomarker-based tests and imaging solutions are enabling faster and more accurate identification of cancer, which is significantly improving patient outcomes.

Technological Advancements Accelerating Precision
Rapid advancements in molecular diagnostics, next-generation sequencing, and immunohistochemistry have elevated the market’s precision capabilities. Over 42% of diagnostic developments now leverage these technologies to enhance specificity and sensitivity. The integration of artificial intelligence and machine learning is further enhancing diagnostic workflows, reducing time-to-result and improving diagnostic accuracy

Growing Preference for Non-Invasive Diagnostics
The shift toward non-invasive and minimally invasive testing methods is gaining momentum, with adoption growing by over 38%. Liquid biopsies and blood-based tests are replacing conventional tissue biopsies in many instances, owing to their safety, ease, and rapid result delivery. These innovations are increasing patient compliance and expanding accessibility to diagnostics.

Rising Incidence Fueling Testing Volumes
A consistent rise in cancer prevalence is directly influencing the volume of diagnostics conducted worldwide. Demand for diagnostic procedures has grown by 40%, especially in high-risk populations. This surge has prompted healthcare providers and diagnostic companies to focus on scalable, automated platforms to manage growing testing requirements efficiently.

Strategic Collaborations Enhancing Market Capabilities
The market is witnessing over 30% of growth initiatives through strategic collaborations and acquisitions, aimed at broadening test portfolios and technological capabilities. Collaborations between biotech firms and diagnostic companies are enabling faster development of multi-cancer detection assays and improving their availability across clinical settings.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Coverage
    3. Market Snapshot, By Test Type
    4. Market Snapshot, By Application
    5. Market Snapshot, By Region
  4. Cancer Diagnostics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Incidence of Cancer
        2. Growing Aging Population
        3. Emphasis on Early Detection and Screening
        4. Rising Demand for Personalized Medicine
      2. Restraints
        1. Limited Access to Advanced Diagnostics in Developing Regions
        2. Regulatory Challenges and Compliance Issues
        3. Lack of Skilled Healthcare Professionals
        4. Concerns Regarding Radiation Exposure
      3. Opportunities
        1. Development of Non-invasive Diagnostic Technologies
        2. Integration of Artificial Intelligence and Machine Learning
        3. Adoption of Point-of-Care Testing
        4. Public-Private Partnerships and Collaborations
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Cancer Diagnostics Market, By Product, 2021 - 2031 (USD Million)
      1. Next-Generation Sequencing
      2. Microarrays
      3. In situ Hybridization
      4. Polymerase Chain Reaction (PCR)
      5. Flow Cytometry
      6. Immunohistochemistry
      7. Magnetic Resonance Imaging (MRI)
      8. Computed Tomography (CT)
      9. Positron Emission Tomography (PET)
      10. Ultrasound
      11. Biopsy
      12. Mammography
      13. Others
    2. Cancer Diagnostics Market, By Coverage, 2021 - 2031 (USD Million)

      1. Public Insurance

      2. Private Insurance

    3. Cancer Diagnostics Market, By Test Type, 2021 - 2031 (USD Million)

      1. Biopsy

        1. Fine-Needle Aspiration

        2. Core Biopsy

        3. Surgical Biopsy

        4. Skin Biopsy /Punch Biopsy

        5. Others

      2. Others

    4. Cancer Diagnostics Market, By Application, 2021 - 2031 (USD Million)
      1. Colorectal Cancer
      2. Breast Cancer
      3. Lung Cancer
      4. Cervical Cancer
      5. Kidney Cancer
      6. Liver Cancer
      7. Pancreatic Cancer
      8. Others
    5. Cancer Diagnostics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Abbott
      2. Qiagen
      3. F. Hoffmann-La Roche Ltd
      4. Siemens Healthcare GmbH
      5. Thermo Fisher Scientific Inc
      6. GE Healthcare
      7. Hologic Inc
      8. Illumina Inc
      9. Philips Healthcare
  7. Analyst Views
  8. Future Outlook of the Market